O	0	3	The
O	4	10	effect
O	11	13	of
O	14	16	an
B-intervention	17	24	aerobic
I-intervention	25	33	exercise
O	34	38	bout
O	39	41	24
O	42	43	h
O	44	49	prior
O	50	52	to
O	53	57	each
O	58	69	doxorubicin
O	70	79	treatment
O	80	83	for
O	84	90	breast
O	91	97	cancer
O	98	100	on
O	101	108	markers
O	109	111	of
B-condition	112	126	cardiotoxicity
O	127	130	and
O	131	140	treatment
O	141	149	symptoms
O	149	150	:
O	151	152	a
O	153	156	RCT
O	156	157	.

O	158	160	In
O	161	168	rodents
O	168	169	,
O	170	171	a
O	172	178	single
O	179	187	exercise
O	188	192	bout
O	193	202	performed
O	203	205	24
O	206	207	h
O	208	213	prior
O	214	216	to
O	217	218	a
O	219	225	single
O	226	237	doxorubicin
O	238	247	treatment
O	248	256	provides
O	257	263	cardio
O	263	264	-
O	264	274	protection
O	274	275	.

O	276	280	This
O	281	286	study
O	287	299	investigated
O	300	307	whether
O	308	318	performing
O	319	323	this
O	324	336	intervention
O	337	342	prior
O	343	345	to
O	346	351	every
O	352	363	doxorubicin
O	364	373	treatment
O	374	377	for
O	378	384	breast
O	385	391	cancer
O	392	399	reduced
O	400	411	subclinical
O	412	426	cardiotoxicity
O	427	430	and
O	431	440	treatment
O	441	449	symptoms
O	449	450	.

B-total-participants	451	457	Twenty
I-total-participants	457	458	-
I-total-participants	458	462	four
B-eligibility	463	468	women
I-eligibility	469	473	with
I-eligibility	474	479	early
I-eligibility	480	485	stage
I-eligibility	486	492	breast
I-eligibility	493	499	cancer
O	500	504	were
O	505	513	randomly
O	514	522	assigned
O	523	525	to
O	526	533	perform
O	534	535	a
O	536	538	30
O	538	539	-
O	539	542	min
O	542	543	,
O	544	552	vigorous
O	552	553	-
O	553	562	intensity
O	563	572	treadmill
O	573	577	bout
O	578	580	24
O	581	582	h
O	583	588	prior
O	589	591	to
O	592	596	each
O	597	599	of
O	600	604	four
O	605	616	doxorubicin
O	616	617	-
O	617	627	containing
O	628	640	chemotherapy
O	641	651	treatments
O	652	654	or
O	655	657	to
B-control	658	663	usual
I-control	664	668	care
O	668	669	.

O	670	681	Established
O	682	699	echocardiographic
O	700	703	and
O	704	715	circulating
O	716	726	biomarkers
O	727	729	of
O	730	741	subclinical
O	742	756	cardiotoxicity
O	756	757	,
O	758	760	as
O	761	765	well
O	766	768	as
O	769	774	blood
O	775	783	pressure
O	784	787	and
O	788	792	body
O	793	799	weight
O	800	804	were
O	805	813	measured
O	814	820	before
O	821	824	the
O	825	830	first
O	831	834	and
O	835	836	7
O	836	837	-
O	837	839	14
O	840	844	days
O	845	850	after
O	851	854	the
O	855	859	last
O	860	869	treatment
O	869	870	.

O	871	874	The
O	875	884	Rotterdam
O	885	892	symptom
O	893	902	checklist
O	903	906	was
O	907	911	used
O	912	914	to
O	915	921	assess
O	922	929	patient
O	929	930	-
O	930	938	reported
O	939	947	symptoms
O	947	948	.

O	949	952	The
O	953	961	exercise
O	962	965	and
O	966	971	usual
O	972	976	care
O	977	983	groups
O	984	987	did
O	988	991	not
O	992	998	differ
O	999	1001	in
O	1002	1005	the
B-outcome	1006	1017	doxorubicin
I-outcome	1017	1018	-
I-outcome	1018	1025	related
I-outcome	1026	1032	change
I-outcome	1033	1035	in
I-outcome	1036	1048	longitudinal
I-outcome	1049	1055	strain
I-outcome	1055	1056	,
I-outcome	1057	1062	twist
I-outcome	1062	1063	,
I-outcome	1064	1066	or
I-outcome	1067	1074	cardiac
I-outcome	1075	1083	troponin
O	1083	1084	.

O	1085	1092	However
O	1092	1093	,
O	1094	1097	the
O	1098	1102	four
O	1103	1108	total
O	1109	1117	exercise
O	1118	1123	bouts
O	1124	1133	prevented
B-outcome	1134	1141	changes
I-outcome	1142	1144	in
I-outcome	1145	1157	hemodynamics
O	1158	1159	(
O	1159	1168	increased
O	1169	1176	cardiac
O	1177	1183	output
O	1183	1184	,
O	1185	1192	resting
O	1193	1198	heart
O	1199	1203	rate
O	1203	1204	,
O	1205	1214	decreased
O	1215	1223	systemic
O	1224	1232	vascular
O	1233	1243	resistance
O	1243	1244	,
O	1245	1246	p
O	1247	1248	<
O	1249	1250	0
O	1250	1251	.
O	1251	1253	01
O	1253	1254	)
O	1255	1258	and
O	1259	1266	reduced
B-outcome	1267	1271	body
I-outcome	1272	1278	weight
I-outcome	1279	1283	gain
O	1283	1284	,
B-outcome	1285	1295	prevalence
I-outcome	1296	1298	of
I-outcome	1299	1308	depressed
I-outcome	1309	1313	mood
O	1313	1314	,
B-outcome	1315	1319	sore
I-outcome	1320	1327	muscles
O	1327	1328	,
O	1329	1332	and
B-outcome	1333	1336	low
I-outcome	1337	1341	back
I-outcome	1342	1346	pain
O	1347	1352	after
O	1353	1356	the
O	1357	1361	last
O	1362	1371	treatment
O	1372	1373	(
O	1373	1374	p
O	1375	1376	<
O	1377	1378	0
O	1378	1379	.
O	1379	1381	05
O	1381	1382	)
O	1383	1391	relative
O	1392	1394	to
O	1395	1398	the
O	1399	1404	usual
O	1405	1409	care
O	1410	1415	group
O	1415	1416	.

B-outcome	1417	1419	No
I-outcome	1420	1427	adverse
I-outcome	1428	1434	events
O	1435	1443	occurred
O	1443	1444	.

O	1445	1447	An
O	1448	1456	exercise
O	1457	1461	bout
O	1462	1471	performed
O	1472	1474	24
O	1475	1476	h
O	1477	1482	prior
O	1483	1485	to
O	1486	1491	every
O	1492	1503	doxorubicin
O	1504	1513	treatment
O	1514	1517	did
O	1518	1521	not
O	1522	1526	have
O	1527	1529	an
O	1530	1536	effect
O	1537	1539	on
O	1540	1547	markers
O	1548	1550	of
O	1551	1562	subclinical
O	1563	1577	cardiotoxicity
O	1577	1578	,
O	1579	1582	but
O	1583	1586	had
O	1587	1588	a
O	1589	1597	positive
O	1598	1606	systemic
O	1607	1613	effect
O	1614	1616	on
O	1617	1629	hemodynamics
O	1629	1630	,
O	1631	1646	musculoskeletal
O	1647	1655	symptoms
O	1655	1656	,
O	1657	1661	mood
O	1661	1662	,
O	1663	1666	and
O	1667	1671	body
O	1672	1678	weight
O	1679	1681	in
O	1682	1687	women
O	1688	1692	with
O	1693	1699	breast
O	1700	1706	cancer
O	1706	1707	.

O	1708	1709	A
O	1710	1716	single
O	1717	1725	exercise
O	1726	1730	bout
O	1731	1736	prior
O	1737	1739	to
O	1740	1752	chemotherapy
O	1753	1763	treatments
O	1764	1767	may
O	1768	1770	be
O	1771	1772	a
O	1773	1779	simple
O	1780	1788	clinical
O	1789	1797	modality
O	1798	1800	to
O	1801	1807	reduce
O	1808	1816	symptoms
O	1817	1820	and
O	1821	1827	weight
O	1828	1832	gain
O	1833	1838	among
O	1839	1844	women
O	1845	1849	with
O	1850	1856	breast
O	1857	1863	cancer
O	1863	1864	.
